AI Day1 LLC - Oct 18, 2023 Form 4 Insider Report for Day One Biopharmaceuticals, Inc. (DAWN)

Role: 10%+ Owner
Signature: /s/ Alejandro Moreno for AI Day1 LLC
Stock symbol: DAWN
Transactions as of: Oct 18, 2023
Transactions value $: $14,978,327
Form type: 4
Date filed: 10/20/2023, 04:02 PM
Previous filing: Jun 12, 2023
Next filing: Aug 5, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	DAWN	Common Stock	Purchase	$10M	+980K	+8.55%	$10.21	12.4M	Oct 18, 2023	Direct	F1, F2
transaction	DAWN	Common Stock	Purchase	$3.87M	+384K	+3.09%	$10.06	12.8M	Oct 19, 2023	Direct	F2, F3
transaction	DAWN	Common Stock	Purchase	$1.11M	+111K	+0.87%	$9.97	12.9M	Oct 20, 2023	Direct	F2, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in Column 4 is a weighted average purchase price of the shares of common stock. The shares of common stock were purchased in multiple transactions ranging from $10.07 to $10.29 inclusive. The reporting persons undertake to provide to Day One Biopharmaceuticals, Inc., any security holder of Day One Biopharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares of common stock purchased at each separate price within the ranges set forth in this footnote to this Form 4.
F2	The securities reported are held directly by AI Day1 LLC and may be deemed to be beneficially owned by Access Industries Holdings LLC ("AIH"), Access Industries Management, LLC ("AIM") and Len Blavatnik because AIH indirectly controls all of the outstanding voting interests in AI Day1 LLC, AIM controls AIH and Mr. Blavatnik controls AIM and controls a majority of the outstanding voting interests in AIH. AIH, AIM and Mr. Blavatnik each disclaims beneficial ownership of these securities, except to the extent of its or his pecuniary interest therein, and this form shall not be construed as an admission that any such reporting person is the beneficial owner of any of the securities reported on this form.
F3	The price reported in Column 4 is a weighted average purchase price of the shares of common stock. The shares of common stock were purchased in multiple transactions ranging from $9.88 to $10.20 inclusive. The reporting persons undertake to provide to Day One Biopharmaceuticals, Inc., any security holder of Day One Biopharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares of common stock purchased at each separate price within the ranges set forth in this footnote to this Form 4.
F4	The price reported in Column 4 is a weighted average purchase price of the shares of common stock. The shares of common stock were purchased in multiple transactions ranging from $9.83 to $10.13 inclusive. The reporting persons undertake to provide to Day One Biopharmaceuticals, Inc., any security holder of Day One Biopharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares of common stock purchased at each separate price within the ranges set forth in this footnote to this Form 4.